Trials / Completed
CompletedNCT02692716
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 3,183 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This trial is conducted globally. The aim of the trial is to investigate the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | semaglutide | For oral use once daily. |
| DRUG | placebo | For oral use once daily. |
Timeline
- Start date
- 2017-01-17
- Primary completion
- 2018-09-25
- Completion
- 2018-09-25
- First posted
- 2016-02-26
- Last updated
- 2022-07-20
- Results posted
- 2020-02-27
Locations
228 sites across 21 countries: United States, Algeria, Argentina, Brazil, Canada, Denmark, Germany, India, Israel, Italy, Malaysia, Mexico, Netherlands, Poland, Romania, South Africa, Spain, Taiwan, Thailand, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT02692716. Inclusion in this directory is not an endorsement.